Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges

糖尿病肾病：药物发现和临床开发挑战

• 批准号: 8785323
• 负责人: Frank C Brosius
• 金额: $ 1万
• 依托单位: NEW YORK ACADEMY OF SCIENCES
• 依托单位国家: 美国
• 财政年份: 2014
• 资助国家: 美国
• 起止时间: 2014-07-01 至 2015-06-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/8785323
• 关键词: Academia; Academy; Albuminuria; Angiotensins; Animal Model; Anti-Inflammatory Agents; Anti-inflammatory; Area; Award; Basic Science; Benefits and Risks; Biological Markers; Blood capillaries; Caring; Cells; Child; Chronic Kidney Failure; Clinic; Clinical; Clinical Data; Clinical Investigator; Clinical Trials; Collaborations; Communities; Complications of Diabetes Mellitus; Congresses; Consensus; Coupled; Data; Development; Diabetes Mellitus; Diabetic Nephropathy; Diagnostic; Digestive System Disorders; Disabled Persons; Disease; Disease Association; Drug Industry; Educational workshop; End stage renal failure; Epidemic; Event; Faculty; Family; Fellowship; Female; Fibrosis; Fostering; Future; Goals; Government; Healthcare Systems; Incidence; Industry; Inflammation; Institutes; International; Kidney; Kidney Diseases; Knowledge; Life; Medical Research; Mentors; Metabolism; Minority Groups; Mission; Molecular; Monitor; Multimedia; New York; New York City; Obesity; Participant; Pathway interactions; Patients; Pharmacologic Substance; Physiology; Pre-Clinical Model; Prevalence; Process; Prognostic Marker; Progressive Disease; Public Health; Publications; Publishing; Research; Research Personnel; Research Training; Resolution; Risk; Role; Science; Scientist; Signal Pathway; Signal Transduction; Technical Expertise; Technology; Therapeutic; Tissues; Translational Research; Translations; Travel; Tubular formation; Underrepresented Minority; United States; Woman; abstracting; advanced disease; base; capillary; career; cell type; data exchange; discount; drug candidate; drug development; drug discovery; improved; innovation; insight; knowledge translation; lectures; mTOR inhibition; meetings; new technology; new therapeutic target; novel; novel therapeutics; outcome forecast; posters; prevent; public health relevance; repository; standard of care; symposium; targeted delivery; treatment strategy

DESCRIPTION (provided by applicant): Diabetic nephropathy (DN), a well-known complication of diabetes, is the leading cause of chronic renal failure and end-stage renal disease (ESRD). The limited efficacy of the standard of care, which only delays the progression to ESRD to a limited extent, coupled with our incomplete understanding of this multifaceted disease, highlights the importance of unraveling novel therapeutic targets. This 1-day scientific symposium titled, "Diabetic Kidney Disease: Drug Discovery and Clinical Development Challenges" will be presented by the New York Academy of Sciences on December 9, 2014, in New York City. This symposium will blend new technologies, target-disease associations, physiology-based insights, and identify novel targets, with the goals of identifying and delivering novel drug candidates into the clinic, improving current treatments, and developing new therapeutic strategies. The event will convene approximately 150 attendees ranging from basic scientists and clinical investigators in academia, industry, and government; to pharmaceutical strategists, and regulatory experts. The three central aims of this conference are to: (i) provide neutral forum through lectures, interactive debates, and networking activities for discussing current hurdles and emerging innovative approaches to DN-targeted therapy, such as preclinical models and clinical trials, signaling pathways, identification of druggable targets, capillary loss and excess anti-angiogenic activity associated with advanced disease states, and targeting the renal microvasculature; (ii) showcase and encourage the participation of early career, female, and underrepresented minority investigators via short talks, poster presentations, travel fellowships, career mentoring activities, and discounted registration; and (iii) foster collaboratin among international investigators from all sectors to promote the translation of research into safer and more efficient diabetic kidney disease therapeutics. The symposium goals align well with the mission of the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) to support medical research and research training. The NIDDK's goal to disseminate science-based information on diabetes and kidney diseases will be met through the symposium's simulcast and archival as a webinar and open-access, online, multimedia Academy eBriefing, and publication of an open-access, Section 508- compliant Meeting Report in Annals of the New York Academy of Sciences, which will distribute the scientific knowledge and ideas exchanged at the symposium to the global research and medical communities. This symposium is especially timely given that a wealth of new data has emerged within distinct research areas (e.g., novel cell types, targets, and therapies) and from varied scientific approaches (e.g., animal models, novel target tissues). A collaborative examination of this new information among all diabetic kidney disease stakeholders is therefore of significant value for guiding research forward in the field - particularly with respect to potential novel targets and delivery of novel drug candidates into the clinic.

描述（申请人提供）：糖尿病肾病（DN）是一种众所周知的糖尿病并发症，是慢性肾功能衰竭和终末期肾病（ESRD）的主要原因。标准治疗的功效有限，只能在有限的程度上延缓终末期肾病的进展，加上我们对这种多方面疾病的不完全了解，凸显了揭示新治疗靶点的重要性。纽约科学院将于 2014 年 12 月 9 日在纽约市举办为期 1 天的科学研讨会，题为“糖尿病肾病：药物发现和临床开发挑战”。本次研讨会将融合新技术、目标疾病关联、基于生理学的见解，并确定新的目标，其目标是确定和交付 新的候选药物进入临床，改进现有的治疗方法，并开发新的治疗策略。此次活动将吸引约 150 名与会者，其中包括学术界、工业界和政府的基础科学家和临床研究人员；制药策略师和监管专家。本次会议的三个中心目标是：（i）通过讲座、互动辩论和网络活动提供中立的论坛，讨论 DN 靶向治疗的当前障碍和新兴创新方法，例如临床前模型和临床试验、信号通路、可药物靶点的识别、毛细血管损失 与晚期疾病状态相关的过度抗血管生成活性，并针对肾脏微血管； (ii) 通过简短演讲、海报展示、旅行奖学金、职业指导活动和折扣注册，展示并鼓励早期职业、女性和代表性不足的少数族裔调查员的参与； (iii) 促进各个部门的国际研究人员之间的合作，以促进研究转化为更安全、更有效的糖尿病肾病治疗方法。研讨会的目标与国家糖尿病、消化和肾脏疾病研究所 (NIDDK) 支持医学研究和研究培训的使命高度契合。 NIDDK 传播有关糖尿病和肾脏疾病的科学信息的目标将通过研讨会的联播和存档（作为网络研讨会和开放获取的在线多媒体学院电子简报）以及在《纽约科学院年鉴》中发布符合第 508 条规定的开放获取会议报告来实现，该报告将分发研讨会上交流的科学知识和想法 全球研究和医学界。鉴于不同研究领域（例如新细胞类型、靶点和疗法）和不同科学方法（例如动物模型、新靶组织）中出现了大量新数据，本次研讨会显得尤为及时。因此，所有糖尿病肾病利益相关者对这一新信息的协作检查对于指导该领域的研究进展具有重要价值，特别是在潜在的新靶点和将新候选药物引入临床方面。